Karyopharm Therapeutics Inc. (KPTI): Revenue
$146.07M
Year ended 2025-12-31
$146.62M
Trailing 12 months to 2026-06-30
-2.4%
3-year compound annual growth
+6.2%
5-year compound annual growth
n/m
10-year compound annual growth
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $146.07M | +0.6% | 2026-02-13, From 2025-01-01 |
| 2024-12-31 | $145.24M | -0.5% | 2026-02-13, From 2024-01-01 |
| 2023-12-31 | $146.03M | -7.0% | 2026-02-13, From 2023-01-01 |
| 2022-12-31 | $157.07M | -25.1% | 2025-02-19, From 2022-01-01 |
| 2021-12-31 | $209.82M | +94.1% | 2024-02-29, From 2021-01-01 |
| 2020-12-31 | $108.08M | +164.3% | 2023-02-17, From 2020-01-01 |
| 2019-12-31 | $40.89M | +34.8% | 2022-03-01, From 2019-01-01 |
| 2018-12-31 | $30.34M | n/m | 2021-02-24, From 2018-01-01 |
| 2017-12-31 | $1.60M | +942.2% | 2020-02-26, From 2017-01-01 |
| 2016-12-31 | $154.0K | -38.4% | 2019-02-28, From 2016-01-01 |
| 2015-12-31 | $250.0K | +9.2% | 2017-03-16, From 2015-01-01 |
| 2014-12-31 | $229.0K | -40.8% | 2017-03-16, From 2014-01-01 |
| 2013-12-31 | $387.0K | -39.0% | 2016-03-15, From 2013-01-01 |
| 2012-12-31 | $634.0K | +317.1% | 2015-03-13, From 2012-01-01 |
| 2011-12-31 | $152.0K | n/a | 2014-03-21, From 2011-01-01 |
Revenue at similar companies
| Company | Year ended | Revenue | Change YoY |
|---|---|---|---|
| Karyopharm Therapeutics Inc. (KPTI) | 2025-12-31 | $146.07M | +0.6% |
| Elite Pharmaceuticals Inc (ELTP) | 2026-03-31 | $148.87M | +77.1% |
| Macrogenics Inc (MGNX) | 2025-12-31 | $149.50M | -0.3% |
| Heron Therapeutics, Inc. (HRTX) | 2025-12-31 | $154.90M | +7.4% |
| Liquidia Corp (LQDA) | 2025-12-31 | $158.32M | n/m |
| Lifecore Biomedical, Inc. (LFCR) | 2025-05-25 | $128.87M | +0.5% |
| Xencor Inc (XNCR) | 2025-12-31 | $125.58M | +13.7% |
| Syndax Pharmaceuticals Inc (SNDX) | 2025-12-31 | $172.35M | +627.8% |
| Phathom Pharmaceuticals, Inc. (PHAT) | 2025-12-31 | $175.11M | +216.9% |
Compare KPTI, ELTP, MGNX, HRTX side by side · Screen every company in Pharmaceutical Preparations ↗